SVB Leerink Upgrades Calithera Biosciences to Outperform, Raises Price Target to $3
SVB Leerink analyst Jonathan Chang upgrades Calithera Biosciences (NASDAQ:CALA) from Market Perform to Outperform and raises the price target from $1 to $3.
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
Calithera Bioscience Granted European Patent Titled ‘ARGINASE INHIBITOR COMBINATION THERAPIES’
https://register.epo.org/application?number=EP17801266
Calithera Biosciences Q3 EPS $(0.15) Beats $(0.23) Estimate, Sales $6.75M
Calithera Biosciences (NASDAQ:CALA) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.23) by 34.78 percent. This is a 53.13 percent increase over losses of $(0.32) per share
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For November 9, 2021
Companies Reporting Before The Bell
• Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter.
• KT (NYSE:KT) is projected to report earnings for its third quarter.